# US 2011/0086845 A1 · Compositions and Methods for Treating Neurodegenerating Diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0086845 A1
- Document ID: US20110086845A1
- Status: Published application
- Kind: A1
- Application number: 12/906,914
- Filed: 2010-10-18
- Published: 2011-04-14
- Earliest claimed: 2007-07-10
- Assignees: The Board of Trustees of the University of Illinois
- Inventors: Douglas L. Feinstein; Maria Vittoria Simonini; Sergey Kalinin; Paul E. Polak
- Web page: https://patentgrep.com/patent/US20110086845A1

## CPC

- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides agents, compositions, pharmaceutical compositions and methods for treating or slowing the progression of a neurodegenerating disease, such as Alzheimer's disease and a demyelinating disease.

## Claims

### Claim 1

A method of slowing progression of a demyelinating disease in a mammal comprising the step of administering to a mammal suffering from a demyelinating disease a therapeutically effective amount of an agent that increases noradrenaline levels in the mammal's CNS.

### Claim 2 (depends on 1)

The method of claim 1, wherein the agent comprises a noradrenaline precursor.

### Claim 3 (depends on 2)

The method of claim 2, wherein the noradrenaline precursor is (−)-threo-3-(3,4-dihydroxyphenyl)-L-serine (L-DOPS).

### Claim 4 (depends on 2)

The method of claim 2, wherein the agent further comprises at least one of an LAAAD inhibitor, a COMT inhibitor, and a noradrenaline reuptake inhibitor.

### Claim 5 (depends on 4)

The method of claim 4, wherein the agent further comprises a COMT inhibitor.

### Claim 6 (depends on 5)

The method of claim 5, wherein the COMT inhibitor is (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide(entacapone), 3,4-dinitrocatechol (DNC) or 3-methoxy-L-tyrosine (3MT).

### Claim 7 (depends on 6)

The method of claim 6, wherein the COMT inhibitor is entacapone.

### Claim 8 (depends on 4)

The method of claim 4, wherein the agent further comprises an LAAAD inhibitor.

### Claim 9 (depends on 8)

The method of claim 8, wherein the LAAAD inhibitor is carbidopa or benserazide.

### Claim 10 (depends on 9)

The method of claim 9, wherein the LAAAD inhibitor is carbidopa.

### Claim 11 (depends on 4)

The method of claim 4, wherein the agent further comprises a noradrenaline reuptake inhibitor.

### Claim 12 (depends on 11)

The method of claim 11, wherein the noradrenaline reuptake inhibitor is desipramine, atomoxetine, reboxetine, viloxazine, maprotiline, nortriptyline, buproprion, or radafaxine.

### Claim 13 (depends on 12)

The method of claim 12, wherein the noradrenaline reuptake inhibitor is atomoxetine.

### Claim 14 (depends on 2)

The method of claim 2, wherein the agent further comprises an LAAAD inhibitor, a COMT inhibitor and a noradrenaline reuptake inhibitor.

### Claim 15 (depends on 1)

The method of claim 1, wherein the mammal is a human.

### Claim 16 (depends on 15)

The method of claim 15, wherein the demyelinating disease is multiple sclerosis, ischemia, perinatal hypoxia, Alzheimer's disease, Charcot-Marie-Tooth disease, Krabbe Disease, Devic's disease, Guillain-Barre Disesae, encephalitis or brain tumor.

### Claim 17

A method of promoting myelination in a mammal's central nervous system (CNS), said method comprising the step of administering to a mammal in need thereof a therapeutically effective amount of an agent that increases noradrenaline levels in the mammal's CNS.

### Claim 18 (depends on 17)

The method of claim 17, wherein the agent comprises a noradrenaline precursor.

### Claim 19 (depends on 18)

The method of claim 18, wherein the noradrenaline precursor is (−)-threo-3-(3,4-dihydroxyphenyl)-L-serine (L-DOPS).

### Claim 20 (depends on 19)

The method of claim 19, wherein the agent further comprises at least one of an L-aromatic-amino-acid decarboxylase (LAAAD) inhibitor, a Catechol O-methyl transferase (COMT) inhibitor, and a noradrenaline reuptake inhibitor.

### Claim 21 (depends on 20)

The method of claim 20, wherein the COMT inhibitor is (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide(entacapone), 3,4-dinitrocatechol (DNC) or 3-methoxy-L-tyrosine (3MT).

### Claim 22 (depends on 20)

The method of claim 20, wherein the LAAAD inhibitor is carbidopa or benserazide.

### Claim 23 (depends on 20)

The method of claim 20, wherein the noradrenaline reuptake inhibitor is desipramine, atomoxetine, reboxetine, viloxazine, maprotiline, nortriptyline, buproprion, or radafaxine.

### Claim 24 (depends on 20)

The method of claim 20, wherein the agent further comprises an LAAAD inhibitor, a COMT inhibitor and a noradrenaline reuptake inhibitor.

### Claim 25 (depends on 17)

The method of claim 17, wherein the increased noradrenaline levels elicit at least one neural protective effect in the mammal's CNS.

### Claim 26 (depends on 25)

The method of claim 25, wherein the neural protective effect is exerted by a glial cell in the CNS.

### Claim 27 (depends on 26)

The method of claim 26, wherein the glial cell is an astrocyte.

### Claim 28 (depends on 25)

The method of claim 25, wherein the neural protective effect is reduced bone morphogenetic protein expression, increased neurotrophic factor expression, oligodendrocyte progenitor cell (OPC) maturation, or reduced inflammation.

### Claim 29 (depends on 17)

The method of claim 17, wherein the mammal is a human.

### Claim 30 (depends on 29)

The method of claim 29, wherein the human is suffering from a demyelinating disease.

### Claim 31 (depends on 30)

The method of claim 30, wherein the demyelinating disease is multiple sclerosis, ischemia, perinatal hypoxia, Alzheimer's disease, Charcot-Marie-Tooth disease, Krabbe Disease, Devic's disease, Guillain-Barre Disesae, encephalitis or brain tumor.

### Claim 32

A method of slowing the progression of Alzheimer's disease or multiple sclerosis in a mammal, the method comprising the step of administering to a mammal suffering from Alzheimer's disease or multiple sclerosis an agent that increases noradrenaline levels in the mammal's CNS, wherein the agent comprises a noradrenaline precursor and a COMT inhibitor.

### Claim 33 (depends on 32)

The method of claim 32, wherein the noradrenaline precursor is (−)-threo-3-(3,4-dihydroxyphenyl)-L-serine (L-DOPS).

### Claim 34 (depends on 32)

The method of claim 32, wherein the COMT inhibitor is (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide(entacapone), 3,4-dinitrocatechol (DNC) or 3-methoxy-L-tyrosine (3MT).

### Claim 35 (depends on 32)

The method of claim 32, wherein the agent further comprises an LAAAD inhibitor.

### Claim 36 (depends on 35)

The method of claim 35, wherein the LAAAD inhibitor is carbidopa or benserazide.

### Claim 37 (depends on 32)

The method of claim 32, wherein the agent further comprises a noradrenaline reuptake inhibitor.

### Claim 38 (depends on 37)

The method of claim 37, wherein the noradrenaline reuptake inhibitor is desipramine, atomoxetine, reboxetine, viloxazine, maprotiline, nortriptyline, buproprion, or radafaxine.

### Claim 39 (depends on 32)

The method of claim 32, wherein the agent further comprises an LAAAD inhibitor and a noradrenaline reuptake inhibitor.

### Claim 40 (depends on 32)

The method of claim 32, wherein the mammal is a human.

### Claim 41

A method of promoting oligodendrocyte progenitor cell maturation or survival comprising administering to a mammal in need thereof an agent that increases noradrenaline levels in the mammal's CNS, wherein the increased noradrenaline levels promote oligodendrocyte progenitor cell maturation.

### Claim 42 (depends on 41)

The method of claim 41, wherein the agent comprises a noradrenaline precursor.

### Claim 43 (depends on 42)

The method of claim 42, wherein the noradrenaline precursor is (−)-threo-3-(3,4-dihydroxyphenyl)-L-serine (L-DOPS).

### Claim 44 (depends on 42)

The method of claim 42, wherein the agent further comprises at least one of an LAAAD inhibitor, a COMT inhibitor and a noradrenaline reuptake inhibitor.

### Claim 45 (depends on 44)

The method of claim 44, wherein the COMT inhibitor is (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide(entacapone), 3,4-dinitrocatechol (DNC) or 3-methoxy-L-tyrosine (3MT).

### Claim 46 (depends on 44)

The method of claim 44, wherein the LAAAD inhibitor is carbidopa or benserazide.

### Claim 47 (depends on 44)

The method of claim 44, wherein the noradrenaline reuptake inhibitor is desipramine, atomoxetine, reboxetine, viloxazine, maprotiline, nortriptyline, buproprion, or radafaxine.

### Claim 48 (depends on 44)

The method of claim 44, wherein the agent further comprises an LAAAD inhibitor, a COMT inhibitor and a noradrenaline reuptake inhibitor.

### Claim 49

A method of promoting oligodendrocyte progenitor cell maturation or survival comprising contacting an oligodendrocyte progenitor cell with noradrenaline.

### Claim 50 (depends on 49)

An isolated oligodendrocyte progenitor cell obtained according to the method of claim 49.

### Claim 51 (depends on 49)

A pharmaceutical composition comprising a plurality of isolated oligodendrocytes obtained according to claim 49 and a pharmaceutically acceptable excipient, diluent or a carrier.

### Claim 52 (depends on 49)

A method of promoting myelination in a mammal's CNS, said method comprising administering to a mammal in need thereof a therapeutically effective amount of a plurality of isolated oligodentrocyte progenitor cells obtained according to the method of claim 49.

### Claim 53 (depends on 51)

A method of promoting myelination in a mammal's CNS, said method comprising administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 51.

### Claim 54

A pharmaceutical composition comprising a noradrenaline precursor, an LAAAD inhibitor and a noradrenaline reuptake inhibitor.

### Claim 55 (depends on 54)

The pharmaceutical composition of claim 54, wherein the noradrenaline precursor is (−)-threo-3-(3,4-dihydroxyphenyl)-L-serine (L-DOPS).

### Claim 56 (depends on 54)

The pharmaceutical composition of claim 54, wherein the LAAAD inhibitor is carbidopa or benserazide.

### Claim 57 (depends on 54)

The pharmaceutical composition of claim 54, wherein noradrenaline reuptake inhibitor is desipramine, atomoxetine, reboxetine, viloxazine, maprotiline, nortriptyline, buproprion, or radafaxine.

### Claim 58 (depends on 57)

The pharmaceutical composition of claim 57, wherein the noradrenaline reuptake inhibitor is atomoxetine.

### Claim 59 (depends on 54)

The pharmaceutical composition of claim 54 further comprising a COMT inhibitor.

### Claim 60 (depends on 59)

The pharmaceutical composition of claim 59, wherein the COMT inhibitor is (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide(entacapone), 3,4-dinitrocatechol (DNC) or 3-methoxy-L-tyrosine (3MT).
